Second U.S. Patent Issues To Skinvisible, Inc. For Its Novel Polymer Delivery Vehicle

LAS VEGAS, Jan. 30 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (Website: www.skinvisible.com), a topical drug delivery company that out-licenses its family of polymer delivery vehicles, Invisicare(R), to established developers and manufacturers of prescription, as well as over-the-counter, dermatological, medical, cosmetic and skincare products, announced today that it has been issued a second patent by the U.S. Patent and Trademark Office protecting the ‘Polymer Composition’ of the Company’s Invisicare(R) polymer delivery system. When topically applied, Invisicare(R)-formulated products hold active ingredients on the skin for up to four hours -- thereby affording the active ingredients an extended timeframe to perform their intended functions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

Previously, a patent was issued to Skinvisible related to the ‘Method of Manufacturing’ Invisicare(R). A third patent application, related to ‘Methods of Use’ of Invisicare(R), is pending.

“The issuance of this second Invisicare(R) patent protects the unique mechanism by which we can safely deliver formulated products using Invisicare(R) to remain on the skin for extended periods of time, resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. This patent thus represenats another significant milestone for our company, one that continues to validate the novelty of our technology platform, Invisicare(R),” said Terry Howlett, President and CEO of Skinvisible.

About Invisicare(R)

At the heart of Skinvisible’s patented technology and trademarked Invisicare(R) family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. This allows formulated products using Invisicare(R) as their platform to remain on the skin for extended periods of time, thereby affording active agents a prolonged timeframe to perform their intended functions. Products utilizing Invisicare(R) have the proven ability to bond active ingredients to the skin for up to four or more hours. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, these formulated products adhere to the skin’s outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. They allow enhanced delivery performance for a variety of skincare agents resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions wear off as part of the natural exfoliation process of the skin’s outer layer cells.

About Skinvisible Pharmaceuticals, Inc.

Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals is a research-and-development company that has formulated and patented innovative polymer delivery system technology and compositions for topical skin applications. Skinvisible’s primary marketing and sales objective is to license its technology and sell its trademarked polymer delivery vehicles to established dermatological, cosmetic, skincare and pharmaceutical manufacturers.

Forward-Looking Statements

This press release contains ‘forward-looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10QSB for the quarter ending September 30, 2005).

Contacts: Ronald Trahan, APR, President Terry Howlett, President/CEO Ronald Trahan Associates Inc., Skinvisible, Inc., 702-433-7154 781-762-9782, x18

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSkinvisible Pharmaceuticals, Inc.

CONTACT: Ronald Trahan, APR, President of Ronald Trahan Associates Inc.,+1-781-762-9782, ext. 18; or Terry Howlett, President/CEO of Skinvisible,Inc., +1-702-433-7154

MORE ON THIS TOPIC